by Amer Belal  , Shawna Lord  , Rohan V. Mehta  and Alfonso Santos

Received: 28 October 2022;  Published: 19 April 2023;  doi: 10.21926/obm.transplant.2302182

Cryptococcosis is a common invasive fungal infection in solid organ transplant recipients (SOTR) that can be challenging to manage. We discuss a case of disseminated cryptococcosis in a transplant recipient. A 26-year-old woman with a history of ESRD from C1q nephropathy, living-related kidney transplant in early 2012, and allograft nephrectomy in 2015, received a deceased donor kidney transplant (DDKT). Induction after the first transplant was anti-thymocyte globulin (ATG) and maintenance immunosuppression (IS) in [...]

by Kristen R Szempruch  , Alec D Martschenko  , Harendra Arora  , Robert S Isaak  , Ravindra Prasad  , John L Schmitz  , Chuning Liu  , Fei Zou  and Pablo Serrano Rodriguez

Received: 13 February 2023;  Published: 18 April 2023;  doi: 10.21926/obm.transplant.2302181

Fluid management intra- and post-operatively for kidney transplant recipients (KTR) is essential to maintain adequate perfusion to the kidney. 0.9% normal saline (NS) is commonly used, but it can cause hyperchloremic metabolic acidosis, which may result in hyperkalemia and lead to delayed graft function (DGF). Plasma-Lyte A (PA) is an alternative option that has a lower amount of chloride and a neutral pH, which may offset the risk of hyperkalemia. The aim of this study is to determine the incidence of DGF in KTRs [...]

by Michelle N. Bremer  , Garrick J. Gama  , Omkar Rao  , Eugene Golts  , Deepa Kurup  , Aarya Kafi  , Christine M. Lin  , Gordon Yung  and Kamyar Afshar

Received: 28 November 2022;  Published: 10 April 2023;  doi: 10.21926/obm.transplant.2302180

Race, while a social construct, has a strong effect on a person’s health. There is limited data on racial disparities within lung transplantation (LTx), especially for Hispanic recipients. Therefore, the aim of this study was to identify inequalities that may involve this population. We analyzed historical data from the Organ Procurement and Transplantation Network (OPTN) and performed a retrospective review of Hispanic and Caucasian patients who underwent lung transplantation in the United States between May 4, 20 [...]

by Suresh Keshavamurthy  and Cody Russell

Received: 11 January 2023;  Published: 04 April 2023;  doi: 10.21926/obm.transplant.2302179

A boundless spectrum of chronic lung diseases is said to effect over 500 million persons globally. Lung transplantation is a well-established therapeutic option for patients suffering from end-stage lung diseases, however waitlist mortality and primary graft failure remain major determinants as post-transplantation 5-year survival is just above 50 percent. Recent innovations in lung transplantation have been aimed at increasing organ availability, improving allograft quality, function, and longevity. Ex-vivo Lung P [...]

by Leona A. Holmberg  , Michael Linenberger  and Laura Connelly-Smith

Received: 06 May 2022;  Published: 30 March 2023;  doi: 10.21926/obm.transplant.2301178

RICE is salvage therapy for treating CD20+non-Hodgkin lymphoma (NHL). It is combined with G-CSF to collect autologous peripheral blood stem cells (aPBSC). Little data exists, though, on the combination of G-CSF and Plerixafor after RICE in mobilizing adequate number of CD34 cells and the product’s immune content. We report on the results of twenty CD20+ NHL patients after RICE, G-CSF and Plerixafor were given to collect aPBSC. The median number of cells collected was 12.92 × 106 CD34 cells/kg (range 5.44-83.76). Pl [...]

by Kamyar Afshar  , Michelle N Bremer  , Deepa Kurup  , Michael Bernales  , Elizabeth Schonhoft  , Luis Santana  , Caro Davila  , Gina Schooler  , Gordon Yung  , Travis Pollema  and Eugene Golts

Received: 07 November 2022;  Published: 14 March 2023;  doi: 10.21926/obm.transplant.2301177

Lung transplant (LTx) survival and quality of life have been steadily improving, partially from changes in candidate selection for transplantation. There are well-known high-risk factors that lead to poor LTx outcomes, which may be referred to as ‘accounted’ risks. However, there are also other ‘unaccounted’ risks that are not included in the existing model for expected LTx survival to help programs for resource allocation. We performed a retrospective cohort study of all LTx recipients over the age of 18 at UC San [...]

by Deepika Razia  , Ashraf Omar  , Katherine Grief  , Rajat Walia  and Sofya Tokman

Received: 20 November 2022;  Published: 01 March 2023;  doi: 10.21926/obm.transplant.2301176

Careful selection of lung transplant (LT) recipients with cystic fibrosis (CF) may improve outcomes; therefore, we studied the impact of sex and age at the time of LT on long-term survival of patients with CF. LT recipients with CF who received post-LT care at our center between July 1, 2007 and April 30, 2021 were included. The primary outcome was death or retransplantation. Cox proportional hazard analysis and the Kaplan-Meier method were used. Of 59 included LT recipients, the median age at first LT was 28 (22, [...]

by Alfonso H. Santos  , Amer Belal  , Hisham Ibrahim  and Muhannad A. Leghrouz

Received: 19 August 2022;  Published: 21 February 2023;  doi: 10.21926/obm.transplant.2301175

We aimed to identify the non-renal risk factors for simultaneous liver-kidney transplantation (SLKT) vs. liver transplantation alone (LTA) in end-stage liver disease (ESLD) patients with estimated glomerular filtration rate (eGFR) 60 years (OR = 0.25, CI = 0.19-0.32), female recipient sex (OR = 0.48, CI = 0.43-0.54), hepatocellular carcinoma (OR = 0.53, CI = 0.35-0.81), and transplant center procedure volume tercile ranks 3rd (OR = 0.74, CI = 0.62-0.89) and 2nd (OR = 0.78, CI = 0.64-0.95). Model for end-stage liver [...]

by Michelle F. Sener  , Thaddeus Rogozinski  , James S. George  , Deepak Mital  and Douglas P. Slakey

Received: 08 November 2022;  Published: 29 January 2023;  doi: 10.21926/obm.transplant.2301174

Cytomegalovirus (CMV) infection is the most common infection affecting kidney transplant recipients [1]. CMV may be present as asymptomatic viremia or with symptoms ranging from mild to significant tissue-invasive disease [1-3]. Optimal kidney graft function and survival requires that transplant care teams carefully assess individual patient risk of CMV [2, 3]. Appropriate patient surveillance and prophylaxis are essential to ensure the best long-term kidney transplant results. Effective treatment of CMV disease re [...]

by Ashwini Arjuna  , Deepika Razia  , Devika Sindu  , Michael T. Olson  , Lara Schaheen  , Ross M. Bremner  , Rajat Walia  and Kendra McAnally

Received: 25 October 2022;  Published: 06 January 2023;  doi: 10.21926/obm.transplant.2301173

Few reports have described successful lung transplantation from a donor with a history of SARS-CoV-2 infection, and outcomes beyond 3 to 6 months remain unknown. After weighing the urgency and life-saving benefits of lung transplantation against the risk of viral transmission, we successfully performed a bilateral lung transplant from a donor with confirmed SARS-CoV-2 infection with mild symptoms 2 months before donation. At 1 year after transplant, there is no evidence of donor-derived viral transmission, and allo [...]